Edition:
United States

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.39USD
1:27pm EST
Change (% chg)

$-0.02 (-0.59%)
Prev Close
$3.41
Open
$3.41
Day's High
$3.49
Day's Low
$3.36
Volume
4,685
Avg. Vol
23,115
52-wk High
$12.09
52-wk Low
$3.26

Select another date:

Fri, Dec 8 2017

BRIEF-Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics

* EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2yOFk6N Further company coverage:

BRIEF-Novelion Therapeutics Appoints Michael Price As CFO

* NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

BRIEF-Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice

* Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

UPDATE 1-U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A U.S. judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes into its marketing of a cholesterol drug, saying it was "not in the public interest."

BRIEF-Novelion Therapeutics says CEO resigns, posts Q3 results

* Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change

U.S. submits revised plea deal with Novelion's Aegerion to court

BOSTON The U.S. Justice Department on Wednesday unveiled a revised a plea agreement with Aegerion Pharmaceuticals Inc that aimed to appease a federal judge who threatened to reject an earlier version that was part of a $36 million settlement.

U.S. submits revised plea deal with Novelion's Aegerion to court

BOSTON, Nov 1 The U.S. Justice Department on Wednesday unveiled a revised a plea agreement with Aegerion Pharmaceuticals Inc that aimed to appease a federal judge who threatened to reject an earlier version that was part of a $36 million settlement.

U.S. judge says he may reject plea deal with Novelion's Aegerion

BOSTON A U.S. judge on Wednesday said he may reject a plea agreement that was part of Aegerion Pharmaceuticals Inc's recent $36 million settlement with the U.S. Justice Department, saying he was not happy with its sentencing terms.

Select another date: